Meeting
2011 ASCO Annual Meeting
Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.
Authors
S. R. D. Johnston
Royal Marsden Hospital, London, United Kingdom
S. R. D. Johnston , K. A. Gelmon , X. B. Pivot , W. J. Gradishar , A. Conner , D. Kothari , P. Legenne , M. Leigh , L. O'Rourke , R. Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
HER2+
Clinical Trial Registration Number
NCT00667251, NCT01160211, NCT00820222
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS105)
Abstract #
TPS105
Poster Bd #
36G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada
Poster
2014 ASCO Annual Meeting
A phase II study with lead-in safety cohort of cabazitaxel (C) plus lapatinib (L) as therapy for HER2+ metastatic breast cancer (MBC) with intracranial metastases (mets).
First Author: Denise A. Yardley
Poster
2013 ASCO Annual Meeting
Second-line treatment of HER2+ metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study.
First Author: Rinat Yerushalmi
Poster
2013 ASCO Annual Meeting
Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer.
First Author: Helen K. Chew